CCM Duopharma’s H1 profit rises to RM20.99 mln

KUALA LUMPUR: CCM Duopharma Biotech Bhd (CCM) recorded a higher net profit of RM20.99 million for the first half of the financial year ended June 30, 2018, up from RM19.21 million registered in the same period a year ago.

Revenue jumped to RM257.25 million versus RM240.36 million previously.

Group Managing Director Leonard Ariff Abdul Shatar said the company’s revenue and profits improved mainly due to the higher domestic demand from both the private and public health sectors. “CCM Duopharma expects to see continued positive demand from all business segments in tandem with Malaysia’s gross domestic product, which is expected to grow by five per cent this year and in particular the government’s 2018 National Budget allocation of RM4.1 billion for the supply of drugs and consumables to all government hospitals and facilities,” he said in a statement yesterday.

The group are buoyant on the positive outlook for the pharmaceutical industry for the rest of 2018 and would tap into these opportunities by enhancing participation in both the local private and public sectors.

For the current financial period ended June 30, 2018, CCM Duopharma has approved an interim dividend of 1.5 sen per share, amounting to approximately RM9.93 million based on a paid-up capital of 661,881,056 shares.

The interim dividend payout in 2017 was RM6.97 million. - Bernama